OVERVIEW
Entero Therapeutics, Inc. (formerly First Wave BioPharma) is a clinical stage biopharmaceutical company specializing in the development of targeted, orally delivered therapies for gastrointestinal (GI) diseases.
Entero is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its three proprietary technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for multiple gastrointestinal indications; and the biologic adrulipase, a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.
